Purinyl Derivatives Selective SK Channel Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for diseases associated with potassium channel activity, such as asthma and epilepsy, lack effective modulators for SK channels, which are crucial for regulating cellular functions and are implicated in various disorders.

Innovation Solution

Development of novel purinyl derivatives that selectively modulate SK1, SK2, and SK3 channels, providing pharmaceutical compositions for treating or alleviating diseases associated with potassium channel activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments are used for diseases associated with potassium channel activity, then existing therapeutic options are limited, but effective modulators for SK channels are lacking

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidavailability of SK channel modulators

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent segments the broad category of potassium channels into specific SK channel subtypes (SK1, SK2, SK3) and develops modulators that can selectively target these specific subtypes. This segmentation allows for precise therapeutic intervention in diseases associated with SK channel activity while distinguishing between different channel functions.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent employs parameter changes by modifying chemical structures of purinyl derivatives to achieve different levels of selectivity and potency for SK channel subtypes. By varying structural parameters such as substituents on the purinyl core, the patent optimizes the pharmacological profile to address specific therapeutic needs for different diseases.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If novel purinyl derivatives are developed to selectively modulate SK channels, then targeted treatment approach is achieved, but development of new pharmaceutical compositions is required

Engineering Contradiction:

Improveselectivity for SK channelsVSAvoidpharmaceutical composition development

Core Design Contradiction:

Adaptability or versatilityVSEase of manufacture

Solution Approach 1:

The patent creates a universal platform based on purinyl derivatives that can function as modulators for multiple SK channel subtypes (SK1, SK2, SK3). This multi-functional approach allows a single chemical scaffold to address various diseases associated with different SK channel subtypes, reducing the need to develop entirely separate therapeutic agents for each subtype.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent uses purinyl derivatives as intermediary compounds that mediate the interaction between therapeutic agents and SK channels. These derivatives serve as a bridge between the desired therapeutic effect and the biological target, enabling selective modulation of SK channels while providing a foundation for developing various pharmaceutical compositions.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentEP2402341B1Purinyl derivatives and their use as potassium channel modulators

Publication Date: 2017.10.25 SANIONA AS

AI summary

This invention relates to novel purinyl derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels.